ArticleVirus evolution2017
Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network.
Article in Virus evolution, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 69 citations in OpenAlex.
- HIV-1 transmitted drug resistance in Shanghai, 2018-2024: population mobility shapes cross-population TDR transmission dynamics.Emerging microbes & infections · 2026Article
- Phylogenetic Evidence of Local HIV-1 Transmission and Antiretroviral Drug Resistance in the Middle East and North Africa.Viruses · 2026Article
- Article
- Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis.The lancet. HIV · 2025Review
- HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.Open forum infectious diseases · 2025Article
- HIV-1 drug resistance and genetic clustering among ART-treated individuals with virologic failure in Aksu, China.Frontiers in microbiology · 2025Article
- HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.The Journal of antimicrobial chemotherapy · 2024Article
- HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.BMC infectious diseases · 2024Article
- Phylogenetic signatures reveal multilevel selection and fitness costs in SARS-CoV-2.Wellcome open research · 2024Article
- Epidemiological dynamics and molecular characterization of HIV drug resistance in eastern China from 2020 to 2023.Frontiers in microbiology · 2024Article
- Article
- Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi'an, China.Drug design, development and therapy · 2023Article
- Molecular Epidemiology and Trends in HIV-1 Transmitted Drug Resistance in Mozambique 1999-2018.Viruses · 2022Article
- Epidemic Characteristics of HIV Drug Resistance in Hefei, Anhui Province.Pathogens (Basel, Switzerland) · 2022Article
- Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.Antimicrobial agents and chemotherapy · 2022Article
- Plant Lectins: A Review on their Biotechnological Potential Toward Human Pathogens.Current protein & peptide science · 2022Review
- Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China.Frontiers in genetics · 2021Article
- No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2.Nature communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Test-and-treat programs are central to the global control of HIV, but transmitted drug resistance threatens the effectiveness of these programs. HIV mutations conferring resistance to antiretroviral drugs reduce replicative fitness
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.